Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diwu Yanggan formula is a Traditional Chinese Medicine (TCM) decoction developed by the Hubei Provincial Traditional Chinese Medical Hospital. It is primarily investigated for the treatment and prevention of primary liver cancer (hepatocellular carcinoma) and chronic liver diseases. The formula is based on the TCM principle of 'tonifying the kidney to promote liver regeneration and repair.' It is hypothesized to exert its therapeutic effects by modulating the microenvironment of hepatic stem cells, thereby inhibiting tumor progression and promoting tissue repair. In clinical trials, it is often evaluated as part of a comprehensive therapy regimen alongside Western medicine or other TCM formulas like Kangdu Ruanjian and Zuoguiwan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Diwu Yanggan formula.